Lakewood-Amedex reports positive data for diabetic foot ulcer drug candidate

Lakewood-Amedex Biotherapeutics said Nu-3 showed positive MIC data against recent clinical isolates from infected diabetic foot ulcers, including resistant bacteria, as the topical candidate advances in a Phase 2a trial. Topline data are expected in the first quarter of 2027.

Why it matters: - Diabetic foot infections can lead to hospitalization and amputation when they are not controlled early. - Lakewood-Amedex is trying to position Nu-3 as a topical option that kills bacteria quickly and may help address antibiotic resistance. - The company says the data strengthen the case for continuing development of its Bisphosphocin® antimicrobial platform.

What happened: - Lakewood-Amedex Biotherapeutics said Nu-3 produced positive Minimum Inhibitory Concentration, or MIC, data from recent clinical isolates taken from infected diabetic foot ulcers. - The announcement was made Sept. 29, 2026. - Nu-3 is being studied in a Phase 2a trial as a topical treatment for mildly infected diabetic foot ulcers, with topline data expected in the first quarter of 2027. - The isolates came from patients at 14 U.S. medical centers.

The details: - The testing evaluated Nu-3 against clinical isolates collected within the last three years. - The study included resistant and susceptible Staphylococcus aureus, including MRSA and MSSA, plus resistant and susceptible Enterococcus faecalis, including VRE and VSE. - Nu-3 showed consistent activity against all organisms tested. - The MIC results were within the range of prior assay results from 285 clinical isolates across 15 species. - The MIC values were 2 to 8 times lower than the planned clinical trial doses, suggesting a favorable dosing margin and therapeutic window. - Antibacterial activity was not affected by drug resistance phenotype. - Control strains included S. aureus ATCC 29213 and E. faecalis ATCC 29212. - Lakewood-Amedex said the findings showed clear cidal activity against microbes isolated from real-world patients.

Between the lines: - The data are encouraging, but they are still laboratory results, not proof of clinical benefit in patients. - The company is highlighting activity against resistant pathogens because those organisms are a major concern in diabetic foot infections and broader antibiotic resistance. - Lakewood-Amedex framed the results as support for continued study rather than a finished clinical answer.

What's next: - Nu-3 remains in Phase 2a testing for mildly infected diabetic foot ulcers. - Investors and clinicians will be watching the upcoming topline readout in early 2027 for signs that the laboratory signal translates into patient outcomes. - The company says further development of the Bisphosphocin® platform will continue if the clinical program keeps moving forward.

The bottom line: - Lakewood-Amedex has another early signal that Nu-3 can hit hard-to-treat bacteria tied to diabetic foot ulcers, but the next major test is whether that activity holds up in the clinic.